Anders Nordström, Chairman
Mr. Nordström has a long and versatile professional experience from executive positions in Life Science companies such as CFO, Executive Vice President and as a Board Member in global life science companies and Startup companies e.g. Halo Genomics. He has held executive positions in Phadia, Pharmacia as well as in ArthroCare International including international assignments in the US and Canada. He is currently working as Senior Advisor, Business Development at Uppsala Innovation Centre and has served as Chairman of the Board in several companies e.g. OssDsign, Vanadis Diagnostics, ExScale Biospecimen Solutions. Mr. Nordström has a BSc in Business Administration and Economics from University of Uppsala, Sweden.
Ola Winqvist, MD Ph.D
Ola is a Professor of Cellular Immunotherapy, Head of Translational Immunology, and Senior Consultant in Clinical Immunology at the Karolinska Institutet and Karolinska University Hospital. The Swedish Research Council and the Swedish Cancer Society have continuously supported Ola’s research since 1999, and he has received various competitive grants from the European Union and Swedish Governmental Agency for Innovation Systems for the development of immunological therapeutics. Ola has an M.D and Ph.D. from Uppsala University in Sweden, and did his postdoctoral research at the Scripps Research Institute in the United States.
M.Sc. in engineering physics from the Norwegian University of Science and Technology. More than 25 years of experience in various senior positions in the Norsk Hydro Group and as CEO of BioInvent International AB. Chairman of the Boards of iCell Science AB and Gabather AB. Board member of Athera Biotechnologies AB and Arild Capital AB.
Previous appointments (last five years): Board member and CEO of BioInvent International AB, Chairman of the Board of Biotec Pharmacon ASA and Board member of the industry organization Sweden Bio.
Richard Åhlberg, MD Ph.D
PhD in immunology, is chief physician at Karolinska University Hospital. He is an experienced life science board member. He has vast experience from the pharmaceutical industry with focus on immuno-oncology from his previous positions as Medical Director and Business Director Oncology at Roche AB. For five years he was the Country Manager for Aleris Healthcare Sweden.
Karin von Wachenfeldt, Ph.D
Karin has a strong scientific expertise in pharmaceutical development of large and small molecules. She obtained her Ph. D in 1993 from Dept. of Immunotechnology at Lund University. Karin has over 20 years of experience from the pharmaceutical industry (BioInvent, Ixsys Inc. PharmaciaUpjohn, Active Biotech and AstraZeneca) developing drugs for cancer and Respiratory/Inflammation. Since 2011 she is the CEO and co-founder of Truly Translational Sweden AB.